84 results about "Coronary atherosclerosis" patented technology

Disclosed herein is a minimally invasive, radio-frequency device and a method for local and regional vascular therapy, more particularly for passivation of atherosclerotic, inflammatory, and/or vulnerable plaque in blood vessels. Radio-frequency devices of the type described herein constitute an important, inexpensive, disposable, minimally invasive approach for passivation or removal of plaques in various parts of the human body, and, as such, have cardiological applications, such as the treatment of coronary atherosclerosis, as well as other applications, such as the treatment occluded blood vessels in the legs and extremities.

The present invention relates to compositions and methods of treating human subjects with a beta-adrenergic receptor blocking agent (“beta-blocker”) provided in a time-sustained-release delivery system. The time-sustained-release drug delivery systems includes at least three populations of beads, where each population of beads includes a beta-blocker. The beads may be selected from immediate-release beads, enteric-release beads, sustained-release beads, and time-sustained-release beads. The beta-blocker may be selected from acebutolol, atenolol, betaxolol, bisoprolol, esmolol, metoprolol, nebivolol, butoxamine, carteolol, carvedilol, labetalol, nadolol, oxprenolol, penbutolol, propranolol, pindolol, sotalol, and timolol. According to presently preferred embodiments, the beta-blocker is propranolol. The dosage forms of the present invention are useful for treating conditions including hypertension, angina pectoris due to coronary atherosclerosis, hypertrophic subaortic stenosis, congestive heart failure, arrhythmias, angina, anxiety, glaucoma, migraines, esophageal varices, alcohol withdrawal syndrome, irregular heartbeat, tachycardia, tremor, and neuroleptic-induced akathisia. They are also useful in the prophylaxis of migraine headaches.

A method for the removal of cholesterol, triglycerides and other lipids from animal plasma, serum or other suitable blood fractions, as a discontinuous flow system, the method comprising withdrawing blood from a subject, separating the required fraction from the blood and mixing with a solvent mixture which extracts the lipids from the fraction, after which the delipidated fraction is recombined with the blood cells and returned to the subject, wherein the solvent extraction step is carried out separately and remote from the subject. The delipidated fraction is washed with a second solvent before being recombined with the blood cells. To ensure that the delipidated fraction is free from all extraction solvent, the fraction is mixed with an absorbent specific for the solvent that is being removed. The preferred absorbent is a macroporous polymeric bead contained in the pores of a sintered glass or plastic sphere, the being capable of absorbing organic molecules from an aqueous solution. By treating the plasma, serum or other suitable blood fraction of a patient by these methods, the blood rheology of a patient with impaired blood circulation can be improved. Further, a rapid regression of coronary atherosclerosis occurs.

A system and method for quantitative determination of density of vasa vasorum in an arterial wall that utilizes a detection of temporal and/or spatial displacement of blood-flow with the use of intravascular ultrasound system. Locations of extrema in the spatial distribution can be identified to detect vascular defects. The system and method support a clinically-useful application for early detection of indicators of diseases, such as coronary atherosclerosis.

The invention discloses a metabolic marker for diagnosing a coronary heart disease. The metabolic marker comprises one or more of 1-palmitoyl-sn-glycerinum-3-phosphatidylcholine, 1-octadecatetraenoicenoyl-sn-glycerinum-3-phosphatidylcholine, 1-linoleoyl-sn-glycerinum-3-phosphatidylcholine, 1-stearoyl-sn-glycerinum-3-phosphatidylcholine, 1-linoleoyl-2-hydroxy-sn-glycerinum-3-phosphatidyl ethanolamine, 1-linoleoyl-sn-glycerinum-3-phosphatidylcholine, 1-oleoyl-sn-glycerinum-3-phosphatidylcholine, 1-hexadecene acyl-sn-glycerinum-3-phosphatidylcholine, phytosphingosine and hexadecanamide. The metabolic marker provided by the invention can accurately diagnose the coronary heart disease, accurately distinguish patients with the coronary heart disease and healthy persons, can also accurately distinguish the patients with the coronary heart disease from patients with atherosclerosis of coronary artery, and has high accuracy, sensitivity and specificity.

Disclosed is a method for estimating stress and strain of coronary artery blood vessel wall. According to the technical scheme, the method includes: firstly, acquiring a motion field of blood vessel wall tissues generated with blood pressure changes from an IVUS (intravascular ultrasound) gray scale image sequence; and secondly obtaining stress and strain values of points on blood vessel wall cross-section images of each frame. The stress and strain values of the blood vessel wall are directly obtained from the conventional IVUS gray scale image sequence, the algorithm is simple, and application conditions of the method are lowered. By the method compared with the methods based on radiofrequency signal analysis, strain values (including two master strains and a shear strain) of optional-direction points on the blood vessel cross section of each frame image can be calculated, elasticity of the blood vessel wall and plaque tissues can be reflected more comprehensively, and more reliable basis is provided for the analysis on pathogenesis of coronary arterial atherosclerosis, the estimation on vulnerability of atherosclerotic plaque, the prediction on development tendency of the atherosclerotic plaque and the like.

High-nutrient health-care bread is made from flour, sugar, yeast, Chinese yam residue dietary fibers, burdock residue dietary fibers, salvia miltiorrhiza, salt, purple potatoes and beans. A crust of the obtained bread is brown, or golden yellow, or reddish brown or light brown; according to the bread crust texture, the crown is big, the neck is obvious, and the crust is free from cracks or spots and smooth; a bread core is purple or light purple and as smooth as silk; air holes of the bread are fine, dense, uniform and rectangular, hole walls are thin, and the bread has no obvious hollow or solid parts and is in a sponge shape; the bread is soft and high in resilience, can recover fast after being pressed, and has bread empyreumatique taste, sweet and saline taste and light yeast taste; Chinese yam residues and burdock residues contain a great number of usable high-quality dietary fibers and have the good dietary therapy health-care functions for patients with diabetes, colon cancer and the like; the salvia miltiorrhiza can reduce blood fat and restrain coronary atherosclerosis formation.

The invention discloses an application of Esculin to prevent and/or treat terminal advanced glycation end-products disease and Cardio-Cerebral-Vascular Disease, especially for the coronary atherosclerosis and arterial atherosclerosis, which is characterized by the following: cracking of terminal advanced glycation end-products, eliminating superoxide anion radical; protecting organism cell from Free-Raducak Injury; antagonizing Experimentative Hyperlipoidemia and decreasing Carotid Atherosclerosis formation. The invention has low toxicity, easy extraction, vast resource, good prospects, which is a perfect Chinese Herb to cure Cardio-Cerebral-Vascular Disease.

The invention discloses a metabolite marker for diagnosing and distinguishing coronary atherosclerosis and stable angina pectoris. The metabolite marker includes one or more of phosphorylcholine, palmitoylethanolamine, phytosphingosine, phosphatidylcholine, ethyl chenodeoxycholic acid, lysophosphatidyl choline (16:0), lysophosphatidyl choline (18:2) and phosphatidyl inositol (20:4/0:0). When the single metabolite marker is used for diagnosing and distinguishing a patient suffering from the stable angina pectoris and a patient suffering from the coronary atherosclerosis, the ROC areas under the curve (AUC) are greater than 0.7, and the marker has clinical diagnostic significance. When the markers are combined for diagnosis, the AUC is further improved with the increase of the combination number; when all eight markers are combined, the AUC is the highest and is up to 0.985, and the sensitivity and specificity are 97.4% and 98.0% respectively under the condition of an optimal cutoff value. The metabolite marker can accurately diagnose and distinguish the coronary atherosclerosis and the stable angina pectoris and is high in accuracy and good in sensitivity and specificity.

An animal model has been developed where the animals can survive myocardial infarctions caused by diet-induced coronary atherosclerosis, and live with chronic heart failure. This animal model is a result of reduced activity of scavenger receptor class BI (SR-BI) and ApoE and the inducible activity of the Mx1-Cre gene. In a preferred embodiment, the model is a result of crossbreeding two transgenic mouse lines: a knockout of SR-BI (SRBI^−/−) and an impaired ApoE expressor (Apoe^h/h) to generate a strain referred to as Apoe^h/hSRB1^−/− mice, which is then crossbred to mice that carry the inducible Mx1-Cre transgene. The Apoe^h/hSRB1^−/− mouse model is genetically modified, enabling the offspring to rapidly and permanently lower their high blood cholesterol levels caused by dietary challenge. The ability to rapidly and permanently lower blood cholesterol levels in these mice stops and may cause the regression of occlusive coronary atherosclerosis restoring blood flow to the heart, allowing the mice to survive from myocardial infarction and live with chronic heart failure.

The invention discloses a metabolic marker group for diagnosing a coronary heart disease. The metabolic marker group comprises one or more of citramalic acid, methionine, taurine, malic acid, phenylalanine and linoleic acid. In a ROC (receiver operating characteristic) curve evaluation method, under the condition that the AUC (area under curve) is larger than 0.5, the closer the AUC is to 1, the better the diagnosis effect is. A metabolic marker has lower accuracy when the AUC is 0.5-0.7, has certain accuracy when the AUC is 0.7-0.9 and has higher accuracy when the AUC is 0.9 or larger. Verification proves that when the single metabolic marker in the metabolic marker group is used for diagnosing and distinguishing patients with the coronary heart disease from subjects with normal coronary arteries, or diagnosing and distinguishing the patients with the coronary heart disease from patients with coronary atherosclerosis, the AUCs are all 0.7 or larger; when a plurality of the metabolic markers are used in combination, the AUC is closer to 1 than that when the single metabolic marker is used, so that the diagnosis effect is better; when six metabolic markers are used in combination, the AUC is closest to 1, and diagnosing and distinguishing effects are the best.

The invention discloses a metabolism marker used for diagnosing and distinguishing coronary atherosclerosis and coronary heart disease. The metabolism marker comprises one or more of 1-palmityl-sn-glycerin-phosphatidylcholine, 1-octadec n-butane enoyl-sn-glycerin-3-phosphatidylcholine, 1-linoleic acyl-sn-glycerin-3-phosphatidylcholine, 1-stearoyl-sn- glycerin-3-phosphatidylcholine, 1-linoleic acyl-2-hydroxyl-sn- glycerin-3-phosphatidylcholine, 1-linoleic acyl-sn-glycerin-3-phosphatidylcholine, 1-oleoyl-sn-glycerin-3-phosphatidylcholine, hexadecanamide and 1-palm oil acyl-sn-glycerin-3- phosphatidylcholine. The metabolism marker can accurately diagnose the coronary atherosclerosis or the coronary heart disease, can also be used for diagnosing and distinguishing the coronary atherosclerosis and the coronary heart disease, and is high in accuracy, sensitivity and specificity.

A mixture for preventing and treating the free radical oxidizing damage of biologic cells, such as presenile dementia, Parkinson's disease, cerebrosclerosis, apoplexy, cardiovascular disease, tumor, etc is prepared from VC, VE and melatonin.

The invention discloses a dual-mode coronary blood vessel image three-dimensional fusion method and fusion system, and the method comprises the steps: obtaining a blood vessel image in an OCT mode, a blood vessel image in an IVUS mode, and a CAG image of a blood vessel through a blood vessel catheter; extracting a blood vessel three-dimensional skeleton in the CAG image according to the CAG image, and fitting according to the blood vessel three-dimensional skeleton to obtain a blood vessel center line; taking the center line of the blood vessel as a catheter withdrawing path, and respectively mapping the blood vessel image in the OCT mode and the blood vessel image in the IVUS mode to corresponding positions of the catheter withdrawing path of the blood vessel to complete image mapping; performing three-dimensional fusion of an OCT mode and an IVUS mode on the mapped image; the advantages of the three-dimensional CAG image in space, the strong tissue penetrating power of the IVUS and the high resolution of the OCT are fully exerted, more comprehensive information of the blood vessel wall and the coronary atherosclerotic plaque can be obtained, and therefore a more effective basis is provided for computer-assisted diagnosis and treatment of the coronary heart disease, evaluation of the interventional therapy effect and the like.

The invention discloses a metabolic marker for diagnosis of coronary atherosclerosis. The metabolic marker includes one or more of 1-arachidonoyl-2-hydroxy-sn-glycerol-3-phosphatidylethanolamine, 1-eicosenoyl-2-hydroxy-sn-glycerol-3-phosphatidylethanolamine, 1-oleoyl-sn-glycerol-3-phosphatidylcholine, 1- docosahexanoyl-2-hydroxy-sn-glycerol-3-phosphatidylethanolamine, 1-docosapentanoyl-2-hydroxy-sn-glycerol-3-phosphatidylethanolamine, 1-docosapentanoyl-sn-glycerol-3-phosphatidylcholine, 1-stearoyl-sn-glycerol-3 phosphatidylcholine, 1-oleoyl-2-hydroxy-sn-glycerol-3-phosphatidylethanolamine, 1-palmitoyl-2-hydroxy-sn-glycerol-3-phosphatidylethanolamine, 1-palmitoyl-sn-glycerol-3-phosphatidylcholine, and 1-octadecanoyl-2-hydroxy-sn-glycerol-3-phosphatidylethanolamine. The metabolic marker provided by the invention can accurately diagnose and distinguish coronary atherosclerosis patients and healthy people, and has high accuracy, strong sensitivity and specificity.

The invention discloses a biomarker miR-216a and target genes Smad3 and Smad7 relating to vascular endothelial senescence and inflammatory reaction, coronary atherosclerosis of the aged and atherosclerotic plaque stability, and verifies up-regulated expression of the miR-216a in a tissue or blood sample of a patient with atherosclerosis and high specificity expression of the miR-216a in people with unstable atherosclerotic plaque. The invention also discloses the application of the miR-216a and an inhibiting agent in preparation of products for evaluating individual atherosclerotic plaque stability and coronary heart disease occurring risk. The atherosclerotic plaque stability and development are evaluated and predicated by evaluation diagnosis in the early stage of coronary atherosclerosis of the aged through the miR-216a; the miR-216a is of important significance to early treatment and medical cost of coronary atherosclerosis and provides a treatment target and an important basis toclinical applications such as gene therapy and drug therapy.

This invention supplies a drug composition used to prevent angina of coronary arteryosclerosis patients and cure chronic stable anginapectoris. It contains nitrate medicament and HMG-CoA reductase inhibitor two active components. Its clinical test results indicate: the two active components procure unexpected effect and notable synergism, and this ihas crucial meaning to prevent and betimes cure cardiac muscular ischemic disease, to great degree it improves coronary disease patient prognosis.

The invention discloses function and application of a Caspase activation and recruitment domain 3 (Card3) gene in a coronary atherosclerotic heart disease. The Card3 gene knockout mice and heart specific Card3 transgenic mice are taken as objects, and a research is carried out on a myocardial infarction model caused by blocking mice heart ramus descendens anterior arteriae coronariae sinistrae. The result proves that compared with WT mice, the cardiac infarction proportion, and the degrees of myocardial hypertrophy and fibrosis of the Card3 gene knockout mice are obviously inhibited, and the cardiac function is obviously improved; the phenotype of the Card3 transgenic mice is contrary to that of the Card3 gene knockout mice. Consequently, the Card3 gene can promote and increase development and progression of the coronary atherosclerotic heart disease, the Card3 can be used as a drug target for screening the drugs for treating the coronary atherosclerotic heart disease, and the inhibitor of the Card3 can be applied to preparation of a drug for treating the coronary atherosclerotic heart disease.

The invention discloses a marker group for diagnosing and distinguishing coronary arterial atherosclerosis from stable angina pectoris. The marker group comprises one or more of glutathione, beta-hydroxybutyric acid, proline, fumaric acid, phenylalanine and lactic acid. When a single marker is used for diagnosing and distinguishing patients with the stable angina pectoris from patients with the coronary arterial atherosclerosis, the AUCs (areas under curve) of a ROC (receiver operating characteristic) are all 0.7 or larger, and the marker has a clinical diagnosis significance; when the markers are used for diagnosis in combination, with the increase of the combination number, the AUC is further increased and reaches 0.988 when 6 markers are combined, and the sensitivity and the specificity are 98.5% and 98.3% respectively under the optimum cutoff value. The metabolic marker group can accurately diagnose and distinguish the coronary arterial atherosclerosis from the stable angina pectoris, and is high in sensitivity and specificity.

The invention relates a method for preparing a preparation used for treating a coronary atherosclerotic heart disease. The coronary atherosclerotic heart disease is heart disease caused by myocardial ischemia and anoxia as a vessel lomen is blocked owning to coronary atherosclerosis; the coronary atherosclerotic heart disease and coronary artery functionality change (spasm) are called by a joint name of a coronary heart disease which is called coronary heart disease for short and is also called an ischemic heart disease. The method for preparing the preparation used for treating the coronary atherosclerotic heart disease has the advantages that the traditional Chinese medicinal theory is applied and combined with the modern biotechnology for preparing traditional Chinese medicinal materials, heart and blood vessels are regulated, stasis is removed and blood is activated, and blood vessels are softened; qi and blood are tonified comprehensively, purgation-tonifying is realized, heart is strengthened, collaterals are activated, and immunity is regulated, so that the coronary atherosclerotic heart disease is comprehensively treated.

The invention provides a method for identifying a bio-marker of coronary atherosclerotic heart disease (or coronary heart disease, CAD) and a detection kit of the method. The bio-marker is free mannose and glucose obtained by high performance liquid chromatography derived from pre-column PMP in serum. The detection method is a high performance liquid chromatography method derived from pre-column 1-phenyl-5-methyl pyrazolone (PMP). The technical scheme has the advantages of simple pretreatment, short analysis time, reasonable instrument price, compliance with conventional use, simple and easy-to-learn operation steps, high accuracy of detection results, capability of distinguishing normal people from CAD patients by only taking blood, minimal amount of the serum required, less than 1 mL ofthe blood taken and the like. The results show that this analysis method can rapidly quantify the free mannose and the glucose in the serum of the CAD patients, so that the method is of great significance for studying the relationship between the free mannose and the glucose in the serum and CAD and finding new CAD clinical detection markers.

The invention discloses a Chinese herba preparation for treating hypertension. The Chinese herba preparation comprises components in parts by weight as follows: uncaria, rhizoma alismatis, Chinese yams, honeysuckles, ligusticum wallichii, rhizoma atractylodis macrocephalae, wild chrysanthemum flowers, cassia seeds, salvia miltiorrhiza, safflower carthamus, parasitic loranthus, radix scrophulariae, radix ophiopogonis, wolfberry fruits, mulberry leaves and scorpions. The Chinese herba preparation is unique in formula, has the functions of activating blood, removing stasis, calming the liver, suppressing yang, eliminating phlegm, relieving dizziness, nourishing the liver and the kidneys, promoting flow of qi and blood and adjusting the balance of yin and yang of a human body, can be used for treating relevant diseases such as strokes, coronary heart diseases, headaches, dizziness, vertigo and the like which are caused by hypertension, can also reduce blood glucose, blood fat and blood viscosity, can effectively increase blood flow volumes of arteries and veins, reduces the injury degrees of myocardial ischemia and myocardial infarction, reduces blood vessel resistance, restrains coronary atherosclerosis, improves brain tissue microcirculation and adjusts circulatory disturbances, has a good treatment effect on a hypertensive, reduces blood pressure stably, and reduces dependency of a patient on Western medicines. The invention further discloses a preparation method of a capsule of the preparation.

Methamphetamine is a highly addictive psychostimulant that causes profound damage to the brain and other body organs. Post mortem studies of human tissues have linked the use of this drug to diseases associated with aging, such as coronary atherosclerosis, but the molecular mechanism underlying these findings remains unknown. We report now that methamphetamine accelerates cellular senescence in vitro and activates transcription of genes involved in cell-cycle control and inflammation in vivo by stimulating production of the sphingolipid messenger ceramide. This pathogenic cascade is triggered by reactive oxygen species, generated through methamphetamine metabolism via cytochrome P₄₅₀-2D6, which recruit nuclear factor (NF)-KB to induce expression of enzymes in the de novo pathway of ceramide biosynthesis. Inhibitors of ceramide formation prevent methamphetamine-induced senescence and attenuate systemic inflammation and health deterioration in rats self-administering the drug. The results support therapeutic approaches to reduce the adverse consequences of methamphetamine abuse and improve effectiveness of treatments.